



PRESS RELEASE MAY 2nd, 2013

MOBERG DERMA BECOMES MOBERG PHARMA

Moberg Derma AB (OMX: MOB) announced today that the Swedish Companies Registration Office has granted the company's application for a name change to Moberg Pharma AB (publ), in accordance with the decision of the AGM on 23 April 2013.

The rationale for the name change is that the business, through the acquisition of Alterna LLC (renamed Moberg Pharma North America LLC), encompasses more than only skin conditions. However, skin conditions and topical drug delivery will remain core areas of the company.

"The name change is a natural step in the company's development. Today, our activities cover other areas than skin conditions and as we continue to build a different kind of pharmaceutical company, we expect to operate in additional therapeutic areas," said Peter Wolpert, CEO of Moberg Pharma.

Updated contact details and website address are provided below. The company's shares will continue to trade under the ticker symbol MOB on the NASDAQ OMX Nordic Exchange Stockholm.

For further information, please contact:

Peter Wolpert, President and CEO

Mobil: +46 (0)70-735 71 35

Email: peter.wolpert@mobergpharma.se

Magnus Persson, IR

Mobil: +46 (0)73-355 26 01

Email: magnus.persson@mobergpharma.se

About this information

Moberg Pharma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 12:00 noon (CET) on May 2nd, 2013.

About Moberg Pharma

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The company's product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal[®], Jointflex[®], Emtrix[®] and Kaprolac[®]. Emtrix[®] (Nalox[™] in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company's share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se.